OBG subsidiary Noveayr Therapeutics has announced the appointments of former AstraZeneca VP, Respiratory, Simon Manners as CEO and former GSK Senior VP, Respiratory, Darrell Baker as Chairman. Noveayr is the parent company of Pharmaserve NW, which offers contract development and manufacturing for a range of OINDPs, and aerosol pharmaceutical maker Ayrton Saunders. According to the company’s web site, Noveayr has also acquired device technology from Kind Consumer and Senzer in recent years, including the Voke breath-actuated inhaler.
Prior to his most recent role leading the Respiratory franchise at AstraZeneca, Manners held a variety of positions at both GSK and AstraZeneca. He commented, “Noveayr is well positioned to seize many of the opportunities in respiratory medicine and make a positive impact for patients. I am delighted to be leading over 100 dedicated colleagues with deep scientific and technology expertise to launch and develop new medicines.”
Baker led the GSK Respiratory franchise through development of products such as Incruse Ellipta, Anoro Ellipta, Breo/Relvar Ellipta. Since leaving GSK in 2015, Baker has been offering consulting services for development and commercialization of respiratory drugs.
OBG Pharmaceuticals Managing Director Padraic O’Brien said, “We are delighted to be welcoming such highly experienced leaders in Simon and Darrell to the board of Noveayr Therapeutics. Noveayr is a specialist in respiratory medicines, specifically metered dose inhaler technology. We are committed to driving the transition to the next generation of environmentally friendly propellants, through reformulating major existing products and enabling the development of new medicines.”
Read the Noveayr Therapeutics press release.
